drugset / Trial / NCT03464916
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
NaSequentialOpen-labelTreatment
Summary
The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.
Timeline
- Start
- 2018-10-15
- Primary completion
- 2020-08-23
- Completion
- 2022-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR2 Anti-CD38 A2 CAR-T Cells | Cell therapy | — | Intravenous |